Ryvu Therapeutics SA

🇵🇱Poland

Country: 🇵🇱Poland

Ownership: Public

Established: 2007-01-01

Employees: 276

Market Cap: -

Website: http://ryvu.com

Clinical Trials

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Phase 2

Recruiting

Conditions: Non-Hodgkin Lymphoma, B-cell

Interventions: Drug: MEN1703
Drug: Glofitamab

First Posted Date: 2024-08-02

Last Posted Date: 2024-12-16

Lead Sponsor: Ryvu Therapeutics SA

Target Recruit Count: 178

Registration Number: NCT06534437

Locations: 🇵🇱
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej, Biała Podlaska, Poland
🇵🇱
Szpitale Pomorskie Sp. z o.o., Gdynia, Poland
🇵🇱
Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy, Gliwice, Poland

and more 6 locations

RVU120 in Patients with Intermediate or High-risk, Primary or Secondary Myelofibrosis

Phase 2

Recruiting

Conditions: Myelofibrosis

Interventions: Drug: RVU120
Drug: Ruxolitinib

First Posted Date: 2024-05-02

Last Posted Date: 2024-12-17

Lead Sponsor: Ryvu Therapeutics SA

Target Recruit Count: 230

Registration Number: NCT06397313

Locations: 🇮🇹
Policlinico Sant'Orsola-Malpighi, Bologna, Italy
🇮🇹
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
🇮🇹
Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", Catania, Italy

and more 15 locations

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Phase 2

Recruiting

Conditions: High-risk Myelodysplastic Syndrome
Acute Myeloid Leukemia (AML)

Interventions: Drug: RVU120

First Posted Date: 2024-02-20

Last Posted Date: 2024-12-13

Lead Sponsor: Ryvu Therapeutics SA

Target Recruit Count: 94

Registration Number: NCT06268574

Locations: 🇨🇦
L'Hotel Dieu de Quebec, Calgary, Canada
🇨🇦
University of Alberta - Faculty of Medicine & Dentistry, Vancouver, Canada
🇫🇷
Centre Hospitalier Universitaire Grenoble Alpes, la Tronche, France

and more 40 locations

Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: RVU120
Drug: Venetoclax

First Posted Date: 2024-01-05

Last Posted Date: 2024-12-17

Lead Sponsor: Ryvu Therapeutics SA

Target Recruit Count: 98

Registration Number: NCT06191263

Locations: 🇫🇷
Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
🇫🇷
Centre Hospitalier Le Mans, Le Mans, France
🇫🇷
Centre Hospitalier Universitaire De Lille, Lille, France

and more 31 locations

RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: RVU120

First Posted Date: 2021-09-22

Last Posted Date: 2024-12-17

Lead Sponsor: Ryvu Therapeutics SA

Target Recruit Count: 120

Registration Number: NCT05052255

Locations: 🇵🇱
Beskidzkie Centrum Onkologii, Szpital Miejski im., Bielsko-Biała, Poland
🇵🇱
Medical University Early Phase 1 Research Center / Uniwersyteckie Centrum Kliniczne Ośrodek Badań Klinicznych Wczesnych Faz, Gdańsk, Poland
🇵🇱
UCK im. prof. K. Gibińskiego, Katowice, Poland

and more 4 locations

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
High-risk Myelodysplastic Syndrome

Interventions: Drug: RVU120(SEL120)

First Posted Date: 2019-07-16

Last Posted Date: 2024-02-14

Lead Sponsor: Ryvu Therapeutics SA

Target Recruit Count: 112

Registration Number: NCT04021368

Locations: 🇺🇸
Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida, United States
🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 7 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy